Screener
MapLight Therapeutics, Inc. MPLT Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by MapLight Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: MapLight Therapeutics, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:25 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224129
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total current assets | 327,228 | 324,670 |
| Property and equipment, net | 968 | 1,095 |
| Long-term investments | 85,090 | 147,993 |
| Restricted cash | 207 | 207 |
| Right-of-use asset | 5,259 | 5,488 |
| Other assets | 36 | 59 |
| Total assets | $418,788 | $479,512 |
| Liabilities and Stockholders' Equity |
Item 1. Financial Statements.
FAQ
- What is MapLight Therapeutics, Inc.'s restricted cash?
- MapLight Therapeutics, Inc. (MPLT) reported restricted cash of $207K in Q1 2026.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about MapLight Therapeutics, Inc.'s restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude